EN
BR
Qualification and expertise
Highly qualified human resources of scientists and technicians key to the implementation of R&D activities, such resources not fully used by the innovation system in the country.
Why Brazil?
Appearance of ReceptaBio is a consequence of the finding of an expressive set of competitive advantages that Brazil offers for Research and Development (R&D) activities in biotechnology associated with the human health area.
The following feasibility elements can be highlighted:
Highly qualified human resources of scientists and technicians key to the implementation of R&D activities, such resources not fully used by the innovation system in the country.
Excellence centers for scientific and technological research that enable a partnerships strategy for R&D activities, through scientific and technological collaboration of the ReceptaBio researchers with scientists from these centers.
Highly qualified and experienced hospital and medical reference centers for conducting clinical tests.
Access to patients for conducting clinical tests and to tumor banks for conducting in vitro assays.
Costs significantly lower than in developed countries, keeping the quality required for the processes.
Ethical instances and clinical research legislation defined since 1996 (CEP-CONEP-ANVISA) and in constant improvement process.
Development of innovative oncologic drugs for the Brazilian population.